Search Results
Sep 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,
More news about: Pomerantz LLP
Sep 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected]
More news about: Pomerantz LLP
Sep 22, 2025, 12:00 ET Netrio Launches Next Release of NetrioNow to Reinvent Managed Services and Redefine the Customer Experience Industry-wide
collaboration with AI and automation – delivering speed, transparency, and outcomes that matter to customers. "NetrioNow is a game-changer. The Agio team invested tremendous effort and expertise in developing and refining the AgioNow platform, and the customer response and adoption has reflected
More news about: Netrio
Sep 18, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected]
More news about: Pomerantz LLP
Sep 18, 2025, 05:49 ET AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
AGIO) for violations of the securities laws.
More news about: The Schall Law Firm
Sep 13, 2025, 12:30 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,
More news about: Pomerantz LLP